News
The most recent news and industry headlines are presented in this section. Our dedicated team closely observes the pharmaceutical industry and keeps you informed of the most recent developments around the Europe.
European Commission approves JASCAYD® for IPF and PPF treatment in the EU
Saturday, July 18, 2026The European Commission EC has granted marketing authorisation for JASCAYD nerandomilast for the treatment of adults with idiopathic pulmonary fibrosis IPF and progressive pulmonary fibrosis PPF Boehringer Ingelheim announced
ThalassaX Therapeutics doses first patient in U.S. Phase I trial of CS231295
Saturday, July 18, 2026ThalassaX Therapeutics United States Ltd has announced that the first patient has been dosed in its US Phase I clinical trial of CS a brainpenetrant Aurora B kinase selective inhibitor developed
Boehringer Ingelheim Advances Obesity Pipeline with Phase II Trial of Triple Receptor Agonist
Friday, July 17, 2026Boehringer Ingelheim has started a Phase II clinical trial of BI an investigational triple GLPGIPNPY receptor agonist for the treatment of people with obesity and overweight
Umoja Biopharma Receives FDA Clearance to Begin Clinical Trial of UB-VV400 In Vivo CAR T Cell Therapy
Friday, July 17, 2026Umoja Biopharma has received clearance from the US Food and Drug Administration FDA for its Investigational New Drug IND application for UBVV a CDdirected in vivo CAR T cell therapy for adults
Sinopia Biosciences Publishes Preclinical Study Supporting SB-0110 for Parkinson's Disease
Thursday, July 16, 2026Sinopia Biosciences has published preclinical research in Science Translational Medicine highlighting a new approach to treating Parkinsons disease The study supports the development of SB
Kairos Pharma Reports Positive Interim Safety Results from Phase 1 Trial of ENV-105 in EGFR-Mutated Lung Cancer
Thursday, July 16, 2026Kairos Pharma has reported positive interim safety results from its ongoing Phase clinical trial of ENV carotuximab in combination with osimertinib Tagrisso for patients with advanced EGFRmutated nonsmall cell lung cancer NSCLC
FDA Grants Priority Review to Roche’s Gazyva/Gazyvaro for Primary Membranous Nephropathy
Wednesday, July 15, 2026Roche has announced that the US Food and Drug Administration FDA has granted Priority Review to its supplemental Biologics License Application sBLA for GazyvaGazyvaro obinutuzumab as a treatment
FDA Grants Fast Track Designation to SOTIO’s SOT109 for Advanced Colorectal Cancer
Wednesday, July 15, 2026SOTIO Biotech has received Fast Track Designation FTD from the US Food and Drug Administration FDA for SOT its investigational antibodydrug conjugate ADC for the treatment of patients
Armata Pharmaceuticals Secures FDA Agreement on Initial Paediatric Study Plan for AP-SA02
Tuesday, July 14, 2026Armata Pharmaceuticals has received agreement from the US Food and Drug Administration FDA on its Initial Paediatric Study Plan iPSP for APSA supporting the future evaluation of the investigational
DA Approves LEQEMBI IQLIK Subcutaneous Injection for Early Alzheimer’s Disease Treatment
Tuesday, July 14, 2026Eisai and Biogen have received approval from the US Food and Drug Administration FDA for a supplemental Biologics License Application sBLA for LEQEMBI IQLIK lecanemabirmb a onceweekly subcutaneous injection for the initiation treatment of early Alzhe...
